Amyloid β Oligomeric Species Present in the Lag Phase of Amyloid Formation

PLoS One. 2015 May 29;10(5):e0127865. doi: 10.1371/journal.pone.0127865. eCollection 2015.

Abstract

Alzheimer's disease (AD)-associated amyloid β peptide (Aβ) is one of the main actors in AD pathogenesis. Aβ is characterized by its high tendency to self-associate, leading to the generation of oligomers and amyloid fibrils. The elucidation of pathways and intermediates is crucial for the understanding of protein assembly mechanisms in general and in conjunction with neurodegenerative diseases, e.g., for the identification of new therapeutic targets. Our study focused on Aβ42 and its oligomeric assemblies in the lag phase of amyloid formation, as studied by sedimentation velocity (SV) centrifugation. The assembly state of Aβ during the lag phase, the time required by an Aβ solution to reach the exponential growth phase of aggregation, was characterized by a dominant monomer fraction below 1 S and a population of oligomeric species between 4 and 16 S. From the oligomer population, two major species close to a 12-mer and an 18-mer with a globular shape were identified. The recurrence of these two species at different initial concentrations and experimental conditions as the smallest assemblies present in solution supports the existence of distinct, energetically favored assemblies in solution. The sizes of the two species suggest an Aβ42 aggregation pathway that is based on a basic hexameric building block. The study demonstrates the potential of SV analysis for the evaluation of protein aggregation pathways.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / chemistry*
  • Amyloid beta-Peptides / metabolism
  • Humans
  • Peptide Fragments / chemistry*
  • Peptide Fragments / metabolism
  • Protein Aggregates*
  • Protein Aggregation, Pathological*

Substances

  • Amyloid beta-Peptides
  • Peptide Fragments
  • Protein Aggregates
  • amyloid beta-protein (1-42)

Grants and funding

Computing time and computational support for UltraScan III software was provided by the Texas Advanced Computing Centre from UT Austin, and is supported by an NSF Teragrid Allocation grant, TGMCB070038. Helmholtz Association funded this work through the Helmholtz-Portfolio Topics “Technology and Medicine” and “Drug Research”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.